In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been
revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against …

Aberrant activation of the epidermal growth factor receptor (EGFR/ERBB1) by erythroblastic
leukemia viral oncogene homolog (ERBB) ligands contributes to various tumor …

Background Non-small cell lung cancer (NSCLC) cells derived intracellular and extracellular
programmed cell death ligand 1 (PD-L1) promoted cancer progression and drug resistance …

Colorectal cancer (CRC) patients, especially those with deficient mismatch repair
(dMMR)/microsatellite instability-high (MSI-H) tumors, whose sensitivity to immune …

Upregulated expression of immune checkpoint molecules correlates with exhausted
phenotype and impaired function of cytotoxic T cells to evade host immunity. By disrupting …

Lung cancer is a leading cause of cancer-related deaths worldwide. About 10–30% of
patients with non-small cell lung cancer (NSCLC) harbor mutations of the EGFR gene. The …

Abstract Pyruvate kinase M2 (PKM2), a key rate-limiting enzyme of glycolysis, is a critical
regulator in tumor metabolism. PKM2 has been demonstrated to overexpressed in various …

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-
1/programmed cell death ligand-1 axis have significantly shifted the treatment paradigm in …

Background Unraveling the mystery of cell death is one of the most fundamental progresses
of life sciences during the past decades. Regulated cell death (RCD) or programmed cell …

Abstract Rationale: Immune checkpoint inhibitors (ICIs) against the PD-1/PD-L1 pathway
showed limited success in non-small cell lung cancer (NSCLC) patients, especially in those …